Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-27T10:38:10.070Z Has data issue: false hasContentIssue false

Chronic caffeine intake decreases circulating catecholamines and prevents diet-induced insulin resistance and hypertension in rats

Published online by Cambridge University Press:  23 June 2011

Silvia V. Conde
Affiliation:
Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal
Tiago Nunes da Silva
Affiliation:
Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Fisiopatologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal
Constancio Gonzalez
Affiliation:
Departamento de Bioquímica y Biología Molecular y Fisiología, Universidad de Valladolid, Facultad de Medicina, 47005Valladolid, Spain Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC), 47005Valladolid, Spain Ciber de Enfermedades Respiratorias, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, 47005Valladolid, Spain
Miguel Mota Carmo
Affiliation:
Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Fisiopatologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal
Emilia C. Monteiro
Affiliation:
Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Farmacologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal
Maria P. Guarino*
Affiliation:
Centro de Estudos de Doenças Crónicas (CEDOC), Departamento de Fisiopatologia, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Campo Mártires da Pátria, 130, 1169-056Lisbon, Portugal
*
*Corresponding author: Dr Maria Pedro Guarino, fax +351 218803078, email maria.guarino@fcm.unl.pt
Rights & Permissions [Opens in a new window]

Abstract

We tested the hypothesis that long-term caffeine intake prevents the development of insulin resistance and hypertension in two pathological animal models: the high-fat (HF) and the high-sucrose (HSu) diet rat. We used six groups of animals: control; caffeine-treated (Caff; 1 g/l in drinking water during 15 d); HF; caffeine-treated HF (HFCaff); HSu; caffeine-treated HSu (HSuCaff). Insulin sensitivity was assessed using the insulin tolerance test. Blood pressure, weight gain, visceral fat, hepatic glutathione, plasma caffeine, insulin and NO, and serum NEFA and catecholamines were measured. Caffeine reversed insulin resistance and hypertension induced by both the HF and HSu diets. In the HF-fed animals caffeine treatment restored fasting insulin levels to control values and reversed increased weight gain and visceral fat mass. In the HSu group, caffeine reversed fasting hyperglycaemia and restored NEFA to control values. There were no changes either in plasma NO or in hepatic glutathione levels. In contrast, caffeine totally prevented the increase in serum catecholamines induced by HF and HSu diets. To test the hypothesis that inhibition of the sympathetic nervous system prevents the development of diet-induced insulin resistance we administered carvedilol, an antagonist of β1, β2 and also α1 adrenoceptors, to HF and HSu rats. Carvedilol treatment fully prevented diet-induced insulin resistance and hypertension, mimicking the effect of caffeine. We concluded that long-term caffeine intake prevented the development of insulin resistance and hypertension in HF and HSu models and that this effect was related to a decrease in circulating catecholamines.

Type
Full Papers
Copyright
Copyright © The Authors 2011

Insulin resistance and hypertension are core metabolic abnormalities in highly prevalent diseases such as type 2 diabetes, the metabolic syndrome and obstructive sleep apnoea(Reference Kashyap and Defronzo1). Drug development for these diseases has focused on reversal strategies, while preventive interventions are mainly related to lifestyle changes. One of the lifestyle modifications advised is to limit caffeine intake, based on several studies describing that caffeine acutely increases blood pressure(Reference Riksen, Rongen and Smits2) and lowers insulin sensitivity(Reference Moisey, Kacker and Bickerton3, Reference Keijzers, De Galan and Tack4). Recently, the benefits of caffeine withdrawal have been questioned, since a number of epidemiological studies showed no association between long-term coffee consumption, type 2 diabetes risk(Reference van Dam, Willett and Manson5, Reference van Dam and Feskens6) and high blood pressure(Reference Noordzij, Uiterwaal and Arends7Reference Conde, Pinto and Bárbara10), which confirms that acute and chronic caffeine intakes have opposite effects(Reference Arnlov, Vessby and Riserus11, Reference Greenberg, Boozer and Geliebter12).

Besides the discussion on the protective v. deleterious effects of coffee in type 2 diabetes and hypertension, there is also controversy concerning the nature of the compound involved in it. Some authors claim that the beneficial effects of coffee are mediated by caffeine(Reference van Dam, Willett and Manson5, Reference Zheng, Sayama and Okubo13, Reference Lopez-Garcia, van Dam and Rajpathak14) while others support that coffee components, apart from caffeine, are responsible for the protection against type 2 diabetes and cardiovascular disease(Reference Noordzij, Uiterwaal and Arends7, Reference Greenberg, Axen and Schnoll15, Reference Wu, Willett and Hankinson16). Regarding the protective role of caffeine intake in the development of type 2 diabetes, the primary mechanism proposed is weight loss attributed to increased thermogenesis, lipolysis and fat oxidation induced by the drug(Reference van Dam, Willett and Manson5, Reference Zheng, Sayama and Okubo13, Reference Lopez-Garcia, van Dam and Rajpathak14, Reference Cheung, Lee and Ng17); still this hypothesis remains debatable since it has also been observed that long-term coffee consumption does not cause significant weight reduction(Reference Astrup, Breum and Toubro18).

Sporadic caffeine intake has also been correlated with elevated blood pressure(Reference Riksen, Rongen and Smits2, Reference Sung, Whitsett and Lovallo19Reference Pincomb, Lovallo and McKey21) due to sympathetic over-activation by increased catecholamine levels and down-regulation of β-receptors(Reference Benowitz22), antagonism of adenosine receptors(Reference Fredholm, Battig and Holmen23), increased noradrenaline release via direct effects on the adrenal medulla and activation of the renin–angiotensin system(Reference Geleijnse9). However, though caffeine administration raises blood pressure acutely, tolerance to this effect develops rapidly, and heavy coffee drinkers are less likely to show an increase in blood pressure after caffeine intake(Reference Robertson, Wade and Workman24, Reference Myers25). In fact, recent prospective studies even suggest a protective role of high coffee intake against hypertension(Reference Geleijnse9).

In the present study, we tested the effects of long-term caffeine intake, at a dose equivalent to moderate human consumption that was previously shown to produce plasma caffeine levels comparable with those in moderate consumers of caffeinated beverages(Reference Holtzman and Finn26, Reference Gasior, Shoaib and Yasar27) in the prevention of diet-induced insulin sensitivity and hypertension in two pathological animal models, the high-sucrose diet rat and the high-fat diet rat. We found that chronic caffeine consumption prevented the development of insulin resistance and hypertension and led to a decrease in circulating catecholamines in the pathological animal models tested. The present results also showed that the pharmacological inhibition of the sympathetic nervous system with carvedilol (CVD), an antagonist of α1, β1 and β2 adrenoceptors, prevented diet-induced insulin resistance in high-sucrose diet and high-fat diet rats similarly to caffeine. We propose that long-term caffeine administration has a protective effect on the development of diet-induced insulin resistance and hypertension through a decrease in circulating catecholamines.

Methods

Animals and experimental procedures

Experiments were performed in male and female Wistar rats (weight 200–420 g), aged 3 months, obtained from the vivarium of the Faculdade de Ciências Médicas. The animals were kept under temperature and humidity control (21 ± 1°C; 55 ± 10 % humidity) with a 12 h light–12 h dark cycle.

Rats were divided into six groups: (1) control group; (2) caffeine group (Caff); (3) high-fat diet group (HF), a model of the metabolic syndrome(Reference Shearer, Severson and Su28); (4) high-fat diet combined with caffeine intake group (HFCaff); (5) high-sucrose diet group (HSu), a lean model of combined insulin resistance and hypertension(Reference Ribeiro, Lautt and Legare29); (6) the high-sucrose diet combined with caffeine intake group (HSuCaff).

The control group was fed standard chow (7·4 % fat +75 % carbohydrate (4 % sugar) +17 % protein; SDS diets RM1; Probiológica, Sintra, Portugal); the HF group was fed a lipid-rich diet (45 % fat +35 % carbohydrate +20 % protein; Mucedola, Settimo Milanese, Italy) for 21 d; the HSu group was fed standard chow and drank 35 % sucrose (Panlab, Lisbon, Portugal) for 28 d. We chose to submit the HSu rats to a 28 d high-sucrose treatment, since at 21 d the animals were neither insulin resistant nor hypertensive (data not shown).

Caffeine (1 g/l) was administered in drinking water during the last 15 d of the experimental protocol(Reference Gasior, Jaszyna and Munzar30). In the HSuCaff group, sucrose and caffeine were administered in the same bottle.

A second set of experiments was performed to test if the effect of sympathetic blockade on insulin sensitivity was similar to the effect of caffeine in the pathological animal models tested. CVD, an antagonist of α1, β1 and β2 adrenoceptors, was the drug of choice and it was administered at a dose of 0·2 g/l in a 0·5 % methylcellulose solution in the drinking bottles, during the last 15 d of the experimental protocol. Methylcellulose was used to facilitate dissolution of CVD and absorption of the drug(Reference Rodriguez-Perez, Losada and Anabitarte31).

Rats were also divided into six groups: (1) the control group administered the vehicle, 0·5 % methylcellulose in drinking water (MC); (2) the CVD group; (3) the HF group administered the vehicle (HFMC); (4) the HF group treated with CVD (HFCVD); (5) the HSu group administered the vehicle (HSuMC); (6) the HSu group treated with CVD (HSuCVD). Individual daily liquid intake was measured to monitor caffeine and CVD ingestion. Body weight was assessed twice per week. On the last day of the experimental protocol, rats were fasted overnight and allowed free access to caffeine solutions or water. Afterwards, the animals were anaesthetised with intraperitoneal sodium pentobarbital (60 mg/kg) and transferred to a heating pad to maintain body temperature at 37·5 ± 0·5°C throughout the experiment. Animals were euthanised by an intracardiac overdose of pentobarbital.

Principles of laboratory care were followed in accordance with the European Union Directive for Protection of Vertebrates Used for Experimental and Other Scientific Ends (86/609/CEE). Experimental protocols were previously approved by the Ethics Committee for Animal Care and Use at the Faculty of Medical Sciences, New University of Lisbon (FCM-UNL; Faculdade de Ciências Médicas, Universidade Nova de Lisboa).

Measurement of insulin sensitivity

The insulin tolerance test (ITT) was used to measure insulin sensitivity. The ITT is one of the earliest methods developed to assess insulin sensitivity in vivo and provides an estimate of overall insulin sensitivity, correlating well with the ‘gold standard’ hyperinsulinaemic–euglycaemic clamp(Reference Monzillo and Hamdy32). The ITT consists of the administration of an intravenous insulin bolus of 0·1 U (4·5 μg)/kg body weight, after an overnight fast, followed by the measure of the decline in plasma glucose concentration over 15 min at 1 min intervals. The constant rate for glucose disappearance (KITT) was calculated using the formula 0·693/t1/2. Glucose half-time (t1/2) was calculated from the slope of the least-square analysis of plasma glucose concentrations during the linear decay phase. Blood samples were collected by tail tipping and glucose levels were measured with a Glucose Analyzer (1500 YSI Sport; Yellow Springs Instruments, Yellow Spring, OH, USA).

Measurement of blood pressure

To measure mean arterial pressure (MAP), the femoral artery was cannulated under a dissection microscope and the catheter was connected to a pressure transducer and amplifier (model 603; HSE-HA GmgH, Harvard Apparatus, Madrid, Spain). MAP data were acquired with HSE-Harvard PULMODYN W software (Harvard Apparatus).

Plasma caffeine quantification

In the caffeine-treated groups, plasma samples, collected by heart puncture into EDTA precoated tubes, were pre-treated for protein precipitation with perchloric acid (30 %) and neutralised with KOH (4 m)–2-amino-2-hydroxymethyl-propane-1,3-diol (Tris; 0·4 m). Caffeine and its metabolites theobromine, theophyline and paraxanthine were quantified by reverse-phase HPLC with low-pressure gradient with UV detection at 274 nm. The HPLC system consisted of an LC 10-A solvent delivery pump (Shimadzu, Kyoto, Japan), an automatic injector SIL-20AC (Shimadzu), a SPD-6 AV UV-VIS wavelength detector (Shimadzu) and Shimadzu Class VP software to analyse the chromatograms. A low-pressure gradient was used: the initial mobile phase consisted of a solution of 50 mm-KH2PO4 (pH 4·58), with 9 % of methanol and 2 % of acetonitrile running at a flux of 1·5 ml/min. Concentrations of the organic solvents changed throughout the sample run. Standards of caffeine, theophylline, theobromine and paraxanthine were prepared in 5 % of bovine serum albumin and submitted to the same pre-treatment as the biological samples. Identification of the peaks in the biological samples was made by comparison with the retention times of the standards.

Quantification of blood glucose, insulin, NEFA, nitric oxide and catecholamines

In all the experiments, plasma and serum were collected by heart puncture. Insulin, caffeine and NO were determined in plasma; NEFA and catecholamines were determined in serum. Insulin was quantified with an ELISA kit (Mercodia Ultrasensitive Rat Insulin ELISA kit; Mercodia AB, Uppsala, Sweden) and NEFA with a colorimetric assay (Zen-Bio Inc., Research Triangle Park, NC, USA). For NO/NO3 determination, plasma samples obtained were deproteinised by adding two volumes of ethanol (0°C). NO/NO3 concentration was determined by using a selective and sensitive NO/ozone chemiluminescence technique (NO-Analyzer 280; Sievers Research Inc., Boulder, CO, USA). For the quantification of catecholamines in serum, 500 μl of serum samples were purified and catecholamines were extracted using 30 mg OASIS Hlb Wat cartridges (Waters, Waltham, MA, USA) and eluted in 500 μl of mobile phase. A quantity of 100 μl of the samples was directly injected into an HPLC system composed of a Waters 600 controller pump, a Waters C18 (particle size 4 μm) column, a Waters 717 plus autosampler and a Bioanalytical Systems LC-4A electrochemical detector (set at a holding potential of 0·65 mV and a sensitivity of 1 nA). An isocratic elution was used: the mobile phase consisted of a solution of 25 mm-Na2HPO4 with 6 % of methanol (pH 3·55), running at a flux of 1·0 ml/min. The signal coming out of the detector was fed to an analogue to digital converter controlled by Peak Sample Chromatography System Software (Buck Scientific, East Norwalk, CT, USA). Identification and quantification of catecholamines were done against external standards.

Measurement of total hepatic glutathione

Glutathione is the major intracellular non-protein thiol and an important protector against free radical damage. We tested the effects of caffeine on hepatic reduced glutathione stores since it is known that total glutathione is significantly depleted after exposure to oxidative stress and increases in the presence of antioxidant compounds. A sample of the medium lobe of the liver was collected after an abdominal laparotomy and stored at − 80°C in an ultra-low freezer (Heraeus, Madrid, Spain). Approximately 100 mg of the tissue was weighed and homogenised in metaphosphoric acid (5 %) using a Teflon pestle. The homogenate was centrifuged at 12 000 g for 10 min at 4°C and the supernatant fraction was collected and frozen at − 80°C for future use. Total hepatic glutathione was quantified using an enzymic method (HT Glutathione Assay Kit, no. 7511-100-K; Trevigen European, Amsbio, Abingdon, Oxon, UK).

Collection and weight of abdominal fat

Renal, genital and visceral fat was collected after an abdominal laparotomy and weighed.

Drugs and chemicals

Caffeine, paraxanthine, theobromine, theophyline, bovine serum albumin, KH2PO4, KOH, metaphosphoric acid, Na2HPO4, noradrenaline, adrenaline, perchloric acid and Tris were obtained from Sigma-Aldrich (Madrid, Spain). Sucrose was obtained from Panlab. Insulin was commercially available as Humulin® Regular (Lilly, Algés, Portugal) in a concentration of 100 UI/ml (4·5 mg/ml). CVD was kindly provided by Labesfal (Lisbon, Portugal).

Data analysis

Data were evaluated using Graph Pad Prism Software, version 4 (GraphPad Software Inc., San Diego, CA, USA) and was presented as mean values with their standard errors. The significance of the differences between the mean values was calculated by one- and two-way ANOVA with Dunnett's and Bonferroni multiple comparison tests, respectively. Potential relationships between the variables under analysis were explored using Pearson's correlation coefficient. Differences were considered significant at P ≤ 0·05.

Results

The ingestion of caffeine in drinking water (1 g/l) was stable throughout the experiments in all the groups since there were no significant changes in individual daily liquid intake per kg. Liquid intake in the Caff group was 6·78 (sem 0·50) ml/kg per d, which was not significantly different from control (7·23 (sem 0·27) ml/kg per d). Liquid intake in the HF and HSu groups was 5·83 (sem 0·25) and 8·31 (sem 0·40) ml/kg per d, respectively. Liquid intake in the HFCaff and HSuCaff groups was 6·01 (sem 0·19) and 8·08 (sem 0·68) ml/kg per d, respectively. No significant differences were observed within the groups. Food intake was also not significantly different (control, 57·78 (sem 2·05); Caff, 55·03 (sem 5·25); HF, 62·56 (sem 1·99); HFCaff, 60·58 (sem 2·79); HSu, 51·22 (sem 4·51); HSuCaff, 52·78 (sem 3·81) mg/kg per d).

As expected we did not detect the presence of caffeine or its metabolites in control, HF and HSu groups. Plasma caffeine concentration in the Caff group was 3·73 (sem 1·08) μg/ml, in the HFCaff group 3·23 (sem 1·09) μg/ml and 4·34 (sem 1·15) μg/ml in the HSuCaff group. These values were not significantly different and are within the range of 0·37–5·95 μg/ml previously described by Gasior et al. for doses of 0·25–1 mg/ml of caffeine in drinking water in rats(Reference Gasior, Jaszyna and Munzar30). Although we did not monitor the physical activity of the animals we did not observe any behavioural changes during the period of caffeine ingestion.

Fasting glycaemia was not significantly different in control and HF groups although the HSu diet significantly increased fasting glycaemia in comparison with the control group (P < 0·001) (Table 1). Chronic caffeine intake did not modify fasting glycaemia both in the control and HF rats but it reversed hyperglycaemia induced by the HSu diet (P < 0·05) (Table 1).

Table 1 Effect of chronic caffeine intake (1 g/l) on glycaemia and insulinaemia in control rats and in rats fed high-fat and high-sucrose diets

(Mean values with their standard errors for all the individual samples obtained from 9–15 rats)

*** Mean value was significantly different from that of the control rats (P < 0·001; two-way ANOVA with Bonferroni multiple comparison test).

† Mean value was significantly different from that of the rats fed the high-sucrose diet without caffeine (P < 0·05; two-way ANOVA with Bonferroni multiple comparison test).

‡‡‡ Mean value was significantly different from that of the rats fed the high-fat diet without caffeine (P < 0·001; two-way ANOVA with Bonferroni multiple comparison test).

Fasting insulinaemia was 1·80 (sem 0·50) μg/l in control rats. Chronic caffeine intake did not significantly change basal insulin concentrations in control rats. Both the HF and HSu diets caused a significant increase in plasma insulin levels (P < 0·001; Table 1) in comparison with the control group. This effect was reduced to control values by chronic caffeine intake in HF (P < 0·001) but not in HSu rats (Table 1).

Effect of chronic caffeine intake on insulin sensitivity

Fig. 1 represents the effect of chronic caffeine intake (1 g/l) on insulin sensitivity in control, HF and HSu groups. The HF diet induced a decrease in KITT from a control value of 4·49 (sem 0·43) % glucose/min to 3·02 (sem 0·34) % glucose/min (P < 0·05). The HSu diet decreased KITT to 2·68 (sem 0·32) % glucose/min (P < 0·01). Chronic caffeine intake did not modify insulin sensitivity in control animals (KITT Caff = 4·52 (sem 0·23) % glucose/min). In both the HF and HSu diet groups, chronic caffeine intake completely reversed the insulin resistance induced by the diets (KITT HFCaff = 4·26 (sem 0·16) % glucose/min; KITT HSuCaff = 4·07 (sem 0·26) % glucose/min).

Fig. 1 Effect of chronic caffeine intake (1 g/l) on insulin sensitivity in control, high-fat (HF) and high-sucrose (HSu) diet rats, determined by the insulin tolerance test, expressed as constant rate for glucose disappearance (KITT). (□), Without caffeine (n 9–12); (■), with caffeine (n 12–15). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: *P < 0·05, **P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: † P < 0·05, †† P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test).

Effect of chronic caffeine intake on mean arterial pressure

Fig. 2 displays the effect of chronic caffeine consumption on MAP in control, HF and HSu animals. HF and HSu administration induced a significant increase in MAP compared with controls (MAP control = 85·99 (sem 2·15) mmHg; MAP HF = 108·04 (sem 5·30) mmHg; MAP HSu = 104·69 (sem 2·72) mmHg). Chronic caffeine intake did not modify MAP in control animals; however, when administrated to HF and HSu rats, it completely prevented the hypertension induced by both diets (MAP Caff = 85·53 (sem 5·32) mmHg; MAP HFCaff = 86·92 (sem 3·96) mmHg; MAP HSuCaff = 92·13 (sem 1·82) mmHg).

Fig. 2 Effect of chronic caffeine intake (1 g/l) on mean arterial pressure (MAP) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (□), Without caffeine (n 9–12); (■), with caffeine (n 9–15). Values are means, with standard errors represented by vertical bars. ** Mean value was significantly different from that of the control rats not given caffeine (P < 0·01; two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: †P < 0·05, ††P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test).

Effect of chronic caffeine intake on body weight, visceral fat and NEFA

Fig. 3 represents the effects of chronic caffeine intake on weight gain (Fig. 3(a)), visceral fat (Fig. 3(b)) and serum NEFA (Fig. 3(c)). The HF diet caused a significant increase in weight gain per d compared with control animals, whereas the HSu diet did not (control = 1·53 (sem 0·26) g/d; HF = 4·32 (sem 0·45) g/d; HSu: 2·66 (sem 0·25) g/d). Caffeine intake did not significantly modify weight gain either in control or in HSu animals (Caff = 1·14 (sem 0·16) g/d; HSuCaff = 2·51 (sem 0·29) g/d). In contrast, caffeine administration significantly reduced weight gain to 2·39 (sem 0·36) g/d in HF animals (Fig. 3(a)).

Fig. 3 Effect of chronic caffeine intake (1 g/l) on body-weight increment, calculated as total weight variation during the experimental period (a), visceral fat, weighed post-mortem and corrected to body weight (b) and serum NEFA (c) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (□), Without caffeine (n 10–12, n 9–12 and n 9–12 for body-weight increment, visceral fat and NEFA, respectively); (■), with caffeine (n 12–16, n 9–13 and n 10–15 for body-weight increment, visceral fat and NEFA, respectively). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: ** P < 0·01, *** P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). ††† Mean value was significantly different from that of the rats within the same diet group not given caffeine (P < 0·001; two-way ANOVA with Bonferroni multiple comparison test).

The HF diet significantly increased visceral fat compared with control animals (control = 8·48 (sem 0·63) g/kg; HF = 12·70 (sem 0·64) g/kg) while the HSu diet did not (10·99 (sem 0·86) g/kg). Caffeine consumption in control and HSu animals did not significantly modify visceral fat (Caff = 6·91 (sem 0·40) g/kg; HSuCaff = 9·91 (sem 0·97) g/kg) but the effect was significant in the HFCaff group (7·80 (sem 0·90) g/kg), a value similar to control (Fig. 3(b)). Fig. 3(c) shows that while the HF diet did not alter serum NEFA (NEFA control = 389·14 (sem 40·45) μm; NEFA HF = 436·45 (sem 36·23) μm), the HSu diet significantly increased NEFA to 940·62 (sem 89·66) μm. Chronic caffeine intake did not modify NEFA either in control or in HF animals (NEFA Caff = 406·57 (sem 29·55) μm; NEFA HFCaff = 391·67 (sem 38·23) μm); however, it significantly decreased NEFA in the HSu group to 610·24 (sem 41·06) μm. The correlations between both KITT and visceral fat and KITT and NEFA, with and without caffeine treatment, are depicted in Fig. 4. We observed a statistically significant negative correlation between KITT and visceral fat (r − 0·467; P = 0·0071) that is lost upon chronic caffeine treatment (r − 0·181; P = 0·314; Fig. 4(a)). Similarly, a statistically significant correlation was observed between KITT and serum NEFA (r − 0·444; P = 0·014) and this correlation was lost in the caffeine-treated groups (r − 0·148; P = 0·338; Fig. 4(b)).

Fig. 4 Effect of chronic caffeine intake (1 g/l) on the correlations between insulin sensitivity, visceral fat and NEFA in all the animals tested. (a) Caffeine eliminates the correlation between constant rate for glucose disappearance (KITT) and visceral fat mass. (b) Caffeine eliminates the correlation between KITT and serum NEFA. Pearson correlation coefficient was in (a): r − 0·467, P = 0·0071 without caffeine (□, - - -) and r − 0·181, P = 0·314 with caffeine (■, ––); in (b): r − 0·444, P = 0·014 without caffeine (Δ, - - -) and r − 0·148, P = 0·338 with caffeine (▲, - - -). Data represent all the individual samples obtained from control, high-fat and high-sucrose diet rats.

Effect of chronic caffeine intake on total hepatic glutathione and plasma NO/NO3 concentration

Fig. 5(a) shows that the HF and HSu diets significantly decreased the total hepatic glutathione content by 35·37 and 70·40 %, respectively, from a control value of 75·3 (sem 3·85) nmol/mg tissue. Chronic caffeine administration did not significantly modify hepatic glutathione + glutathione disulfide (GSSG) levels (Caff = 83·6 (sem 7·46) nmol/mg tissue; HFCaff = 59·1 (sem 7·55) nmol/mg tissue; HSuCaff = 35·3 (sem 3·28) nmol/mg tissue).

Fig. 5 Effect of chronic caffeine intake (1 g/l) on biomarkers of oxidative status. (a) Effect of caffeine on total hepatic glutathione in control rats and in rats submitted to high-fat (HF) and high-sucrose (HSu) diets. (b) Effect of caffeine on plasma NO/NO3 in control, HF and HSu rats. (□), Without caffeine (n 8–11 and n 8–13 for glutathione and NO, respectively); (■), with caffeine (n 8–12 and n 6–12, for glutathione and NO, respectively). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P < 0·01, ***P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test).

Fig. 5(b) represents the effect of chronic caffeine intake on plasma NO/NO3. The HF diet caused a significant increase in plasma NO/NO3 compared with control animals, whereas the HSu diet did not (control, 15·4 (sem 1·0) μm; HF, 24·1 (sem 2·4) μm; HSu, 12·9 (sem 1·0) μm). Caffeine intake did not modify plasma NO/NO3 in any of the groups tested (Caff, 17·3 (sem 0·7) μm; HFCaff, 22·0 (sem 1·8) μm; HSuCaff, 14·8 (sem 1·2) μm).

Effect of chronic caffeine intake on serum catecholamines

The effect of chronic caffeine intake on serum catecholamines (adrenaline plus noradrenaline) in control, HSu and HF rats is represented in Fig. 6(a). The HSu and HF diets significantly increased plasma catecholamines by 211·9 and 124·1 %, respectively, from a control value of 50·03 (sem 6·91) μm. Chronic caffeine intake did not modify plasma catecholamines in control animals; however, when administered together with the HSu and HF diets, caffeine prevented the increase in circulating catecholamines, suggesting that the metabolic and haemodynamic effects of chronic caffeine intake are mediated by a decrease in sympathetic activation. Moreover, KITT was negatively correlated with plasma catecholamines both in the absence (r − 0·399; P = 0·0484) and presence (r − 0·419; P = 0·009) of caffeine treatment (Fig. 6(b)).

Fig. 6 Effect of chronic caffeine intake (1 g/l) on plasma catecholamine concentration in control, high-sucrose (HSu) and high-fat (HF) diet rats. (a) Effect of caffeine on catecholamine (adrenaline plus noradrenaline) plasma levels. (□), Without caffeine (n 10–16); (■), with caffeine (n 12–16). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P < 0·01, ***P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: †† P < 0·01, ††† P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). (b) Caffeine treatment does not change the correlation between constant rate for glucose disappearance (KITT) and circulating catecholamine (adrenaline plus noradrenaline) plasma levels. Pearson correlation coefficient was r − 0·399, P = 0·0484 without caffeine (○) and r − 0·419, P = 0·009 with caffeine (●). Data represent all the individual samples obtained from control, HF and HSu rats.

Effect of carvedilol on insulin sensitivity and mean arterial pressure

There were no significant changes in individual daily liquid intake per kg in any of the groups tested. Food intake was also not significantly different (data not shown). In the HFMC group there was a decrease in KITT from a control value of 4·90 (sem 0·26) % glucose/min to 3·50 (sem 0·23) % glucose/min. The HSuMC diet decreased KITT to 3·35 (sem 0·19) % glucose/min. CVD did not modify insulin sensitivity in control animals (KITT CVD = 4·68 (sem 0·30) % glucose/min) but it completely reversed the insulin resistance induced by the diets (KITT HFCVD = 4·64 (sem 0·27) % glucose/min; KITT HSuCVD = 5·20 (sem 0·12) % glucose/min) (Fig. 7(a)). CVD significantly decreased fasting glycaemia in the HSuMC group from 1165 (sem 45·6) to 919 (sem 27·5) mg/l. Both the HFMC and HSuMC diets caused a significant increase in plasma insulin levels in comparison with the MC group and this effect was reversed by CVD administration (MC = 2·45 (sem 0·26) μg/l; HFMC = 4·88 (sem 0·30) μg/l; HSuMC = 4·36 (sem 0·37) μg/l; HFCVD = 2·42 (sem 0·42) μg/l; HSuCVD = 1·76 (sem 0·79) μg/l). We also observed that CVD completely restored MAP to control values in HF and HSu rats, as expected due to its anti-hypertensive action (MC = 95·6 (sem 3·79) mmHg; CVD = 97·2 (sem 3·35) mmHg; HFMC = 113·0 (sem 4·07) mmHg; HFCVD = 99·4 (sem 4·59) mmHg; HSuMC = 113·6 (sem 3·19) mmHg; HSuCVD = 99·0 (sem 5·17) mmHg).

Fig. 7 Effect of carvedilol (CVD, 0·2 g/l) and its vehicle, methylcellulose (MC, 0·5 %), on insulin sensitivity and plasma catecholamines in control, high-fat (HF) and high-sucrose (HSu) diet rats. (a) The effect of CVD on insulin sensitivity was determined by the insulin tolerance test and is expressed as constant rate for glucose disappearance (KITT). (□), MC (n 10–17); (■), CVD (n 7–12). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats given MC: *P < 0·05, **P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group given MC: †P < 0·05, †††P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). (b) Effect of CVD on catecholamine (adrenaline plus noradrenaline) plasma levels. (□), MC (n 10–36); (■), CVD (n 5–7). Values are means, with standard errors represented by vertical bars. * Mean value was significantly different from that of the control rats given MC (P < 0·05; two-way ANOVA with Bonferroni multiple comparison test).

Effect of carvedilol on serum catecholamines

The HSuMC and HFMC groups showed a significant increase in plasma catecholamines of 112·4 and 97·9 %, respectively, from a control value of 58·53 (sem 8·88) μm in the MC group. In contrast with caffeine, CVD treatment did not modify plasma catecholamines in any of the groups tested (CVD, 59·2 (sem 17·80) μm; HFCVD, 108·6 (sem 33·14) μm; HSuCVD, 88·8 (sem 32·26) μm; Fig. 7(b)). CVD administration did not significantly modify weight gain, visceral fat, NEFA, hepatic glutathione or NO/NO3 in any of the disease models tested (data not shown).

Discussion

We demonstrated in the present study that chronic caffeine intake prevents the development of insulin resistance and hypertension in high-fat- and high-sucrose-fed rats and induces a pronounced decrease in circulating adrenaline and noradrenaline. Also, the effect of CVD, an antagonist of β1, β2 and α1 adrenoceptors, on insulin sensitivity mimicked the effect of caffeine, supporting the hypothesis that caffeine's beneficial effects are mediated by the inhibition of the sympathetic nervous system.

Chronic caffeine treatment did not significantly change fasting glycaemia both in the control and HF groups, which were normoglycaemic without caffeine treatment(Reference Kim, Ellmerer and Van Citters33), but it totally reversed the hyperglycaemia induced by the HSu diet. Also, in contrast with the acute effects of caffeine on insulin secretion described in the literature(Reference Greenberg, Boozer and Geliebter12), the present results show that plasma insulin levels significantly decreased in the HFCaff group and trend towards a decrease in the HSuCaff group compared with the HF and HSu groups, respectively. In the HFCaff group the reduction of fasting insulinaemia, accompanied by an increase in KITT, indicates that chronic caffeine not only increased insulin sensitivity but also normalised insulin secretion in the HF animals. We do not know at this point if the decrease in plasma insulin levels is a direct effect of caffeine on the pancreas, or simply a negative-feedback mechanism induced by improved peripheral insulin sensitivity at the β-cell. However, previous studies in human subjects have described that caffeinated coffee consumption leads to a reduction of plasma C-peptide concentrations in healthy and in obese women, suggesting that coffee components decrease insulin secretion(Reference Wu, Willett and Hankinson16) and in vitro studies also showed that adenosine regulates insulin secretion by the β-cell(Reference Ismail, El Denshary and Montague34).

In contrast with the HFCaff animals, in the HSuCaff group caffeine restored insulin sensitivity and normoglycaemia but the animals remained hyperinsulinaemic compared with controls. This suggests that in the caffeine-treated sucrose-fed model, insulin action improved sufficiently to maintain glucose homeostasis but not enough to normalise endogenous insulin secretion.

In the HF rats both visceral fat and weight gain increased significantly and caffeine reversed these effects, in agreement with the literature(Reference Greenberg, Boozer and Geliebter12). Weight loss and visceral fat mass decrease induced by long-term caffeine consumption may have been due to increased lipolysis accompanied by increased NEFA oxidation, since circulating NEFA were not elevated compared with control animals. We observed no changes in weight gain or visceral fat mass in the HSu rat treated with caffeine. These results indicate that increased adipose tissue mass is not contributing to insulin resistance in this animal model, which is in accordance with previous results by Kanazawa's group(Reference Kanazawa, Xue and Kageyama35).

In contrast to the HF diet, the HSu diet increased circulating NEFA, indicating augmented lipolysis or decreased NEFA oxidation in the sucrose-fed rats as previously described by others(Reference Delarue and Magnan36). These results may also be due to an increased de novo lipogenesis in adipocytes and liver in this model which, combined with insulin resistance, may lead to enhanced lipolysis and systemic NEFA(Reference Lewis, Carpentier and Adeli37). We have observed that chronic caffeine intake reversed the increase in NEFA induced by the HSu diet. This effect may be related to an augmented activity of 5′-AMP activated protein kinase (AMPK) induced by caffeine that promotes an enhancement in NEFA uptake and oxidation in skeletal muscle(Reference Egawa, Hamada and Kameda38, Reference Raney and Turcotte39). Recently, it has also been shown that caffeine can increase GLUT-4 mRNA in skeletal muscle cells and insulin-independent glucose transport mediated by AMPK(Reference Egawa, Hamada and Kameda38), which may explain the return to normal glycaemia observed in the caffeine-treated rats. Despite the beneficial effects of caffeine on visceral fat in the HF-fed rat and in circulating NEFA in the HSu rat, the correlation analyses show that insulin action loses its dependence of these variables after caffeine treatment.

The insulin-sensitising effect of chronic caffeine treatment may also be directly related to antagonism of adenosine receptors on insulin target tissues. The effect of adenosine on glucose homeostasis is currently a hot-topic area with controversial results: while positive effects of A1 receptor partial agonists are well documented on adipose tissue glucose uptake(Reference Dhalla, Chisholm and Reaven40), studies using adenosine receptor antagonists have shown increases(Reference Espinal, Challiss and Newsholme41), decreases(Reference Han, Hansen and Nolte42) and no effect(Reference Vergauwen, Hespel and Richter43) of these drugs on skeletal muscle glucose uptake. Also, A2B receptor antagonists have been used to increase plasma insulin levels in vivo (Reference Rusing, Muller and Verspohl44) and more recently to reduce insulin resistance(Reference Figler, Wang and Srinivasan45). Clearly, more studies are required to clarify the role of adenosine receptors on glucose homeostasis.

In the present study we also demonstrated that chronic caffeine intake prevents the development of hypertension in HF- and HSu-fed animals. Recently, it has been shown that endothelium-dependent vasodilatation after long-term caffeine administration is enhanced in young healthy men(Reference Umemura, Ueda and Nishioka46), a mechanism by which caffeine treatment could lower blood pressure. However, we did not find any effect of chronic caffeine consumption on NO production, suggesting that NO is involved neither in the prevention of hypertension nor in insulin resistance induced by caffeine. It has also been suggested that caffeine may prevent oxidative damage(Reference Scharf, Prustomersky and Huber47, Reference Varma and Hegde48) which could improve endothelium-dependent vasodilation and insulin action. However, in our experimental setting we observed no changes in total hepatic glutathione, both in HF- and HSu-treated animals. Hepatic glutathione stores are significantly depleted after exposure to oxidative stress(Reference Mytilineou, Kramer and Yabut49) and if administration of caffeine produced significant antioxidant effects, we would expect intracellular hepatic glutathione levels to rise, which did not happen.

Chronic caffeine treatment caused a decrease in circulating catecholamines, suggesting that decreased sympathetic nervous system activation, either at the adrenal medulla or at the sympathetic nerves innervating blood vessels, is involved in the protective effects of caffeine. Adenosine receptor agonists inhibit sympathetic neurotransmission and catecholamine release in several tissues, including the hippocampus(Reference Jackisch, Fehr and Hertting50) and adrenal chromaffin cells(Reference Tseng, Chan and Lo51), when administered acutely. Adenosine receptor antagonists, such as caffeine, increase plasma renin activity, adrenaline and noradrenaline(Reference Robertson, Frolich and Carr52) after acute administration; however, in accordance with the present results, it has been shown that the increase in adrenaline levels induced by a single dose of caffeine is lost with sustained consumption(Reference Debrah, Haigh and Sherwin53).

The present results also show that the adrenergic antagonist, CVD, mimicked the effects of caffeine. As observed with caffeine treatment, CVD totally reversed the hyperglycaemia induced by the HSuMC diet. Plasma insulin levels significantly decreased after CVD treatment in the HFCVD and HSuCVD groups, in contrast to the hypoinsulinaemic effect of caffeine that was observed in the HFCaff but not in the HSuCaff group. Others have also reported that CVD, among other third-generation β-blockers, lack adverse metabolic effects and may actually produce favourable effects on insulin sensitivity(Reference Carella, Antonucci and Conte54, Reference Bhatt, Makwana and Santani55). The mechanisms behind these findings are not yet fully understood but the role of the α1 and β2 adrenoceptor blocking effects of CVD appears to be crucial(Reference Kveiborg, Christiansen and Major-Petersen56). While caffeine significantly decreased weight gain and visceral fat mass in HF rats and circulating NEFA in HSu rats, CVD treatment did not change any of these factors in the experimental groups, although the effect of both drugs on insulin sensitivity was very similar. These results are consistent with the hypothesis that the insulin-sensitising properties of both caffeine and CVD are not directly related with changes in adipose tissue homeostasis. Finally, CVD has also been reported to increase endogenous NO production(Reference Corsetti, Pasini and Assanelli57, Reference Ofluoglu, Pasaoglu and Pasaoglu58), affecting endothelium-dependent vasodilation, a mechanism by which this drug could increase insulin sensitivity(Reference Guarino and Macedo59, Reference Guarino, Correia and Raposo60). We did not find any effect of CVD on NO production in our experimental conditions, suggesting that NO is involved neither in the prevention of hypertension nor in insulin sensitisation induced by CVD.

In conclusion, chronic caffeine administration prevents the development of insulin resistance and hypertension in high-fat- and high-sucrose-fed animals due to a decrease in circulating catecholamines. Treatment with an adrenergic antagonist mimics the protective effects of caffeine against diet-induced insulin resistance by blockade of adrenergic receptors without changes in serum catecholamine concentration. The exact biological mechanism underlying the decrease in circulating catecholamines induced by caffeine remains to be clarified and may involve alterations in the expression of adenosine receptors as well as in the expression of other neurotransmitter receptors and ionic channels(Reference Shi and Daly61, Reference Stonehouse, Adachi and Walcott62).

In conclusion, we have shown that long-term caffeine administration has a protective effect on the development of diet-induced insulin resistance and hypertension in rats. Our work strengthens the conclusions of recent epidemiological studies concerning the protective role of coffee consumption in type 2 diabetes and the metabolic syndrome and helps to support the need for a paradigm shift on advised lifestyle changes, like coffee withdrawal, in insulin-resistant and hypertensive patients.

Acknowledgements

We are very grateful to Elena Gonzalez Muñoz for catecholamine quantification and to Inês Faustino, Ana Carvalho and Lúcia Mirrado for technical support and ‘L'Oréal-Unesco Awards for Women in Science 2009 – Portugal’.

The present study was financially supported by CEDOC/FCT, Portuguese Society of Diabetology (SPD)/Lilly Portugal, BFU2007-61848 and JCyL-GR242, and by L'Oréal-Unesco Awards for Women in Science 2009 – Portugal.

S. V. C. and M. P. G. designed and conducted the study and also wrote the manuscript. T. N. da S. participated in data collection and analysis, M. M. C. and E. C. M. contributed in data interpretation. Catecholamine quantification was performed in the laboratory of C. G.

There are no conflicts of interest.

References

1 Kashyap, SR & Defronzo, RA (2007) The insulin resistance syndrome: physiological considerations. Diab Vasc Dis Res 4, 1319.CrossRefGoogle ScholarPubMed
2 Riksen, NP, Rongen, GA & Smits, P (2009) Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease. Pharmacol Ther 121, 185191.CrossRefGoogle ScholarPubMed
3 Moisey, LL, Kacker, S, Bickerton, AC, et al. (2008) Caffeinated coffee consumption impairs blood glucose homeostasis in response to high and low glycemic index meals in healthy men. Am J Clin Nutr 87, 12541261.CrossRefGoogle ScholarPubMed
4 Keijzers, GB, De Galan, BE, Tack, CJ, et al. (2002) Caffeine can decrease insulin sensitivity in humans. Diabetes Care 25, 364369.CrossRefGoogle ScholarPubMed
5 van Dam, RM, Willett, WC, Manson, JE, et al. (2006) Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. Diabetes Care 29, 398403.CrossRefGoogle ScholarPubMed
6 van Dam, RM & Feskens, EJ (2002) Coffee consumption and risk of type 2 diabetes mellitus. Lancet 360, 14771478.CrossRefGoogle ScholarPubMed
7 Noordzij, M, Uiterwaal, CS, Arends, LR, et al. (2005) Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 23, 921928.CrossRefGoogle ScholarPubMed
8 Jee, SH, He, J, Whelton, PK, et al. (1999) The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 33, 647652.CrossRefGoogle ScholarPubMed
9 Geleijnse, JM (2008) Habitual coffee consumption and blood pressure: an epidemiological perspective. Vasc Health Risk Manag 4, 963970.CrossRefGoogle ScholarPubMed
10 Conde, SV, Pinto, P, Bárbara, C, et al. (2009) Should caffeine be avoided in obstructive sleep apnea? In European Respiratory Society Annual Congress, Vienna, Austria: 2009. Abstracts book P3729.Google Scholar
11 Arnlov, J, Vessby, B & Riserus, U (2004) Coffee consumption and insulin sensitivity. JAMA 291, 11991201.CrossRefGoogle ScholarPubMed
12 Greenberg, JA, Boozer, CN & Geliebter, A (2006) Coffee, diabetes, and weight control. Am J Clin Nutr 84, 682693.CrossRefGoogle ScholarPubMed
13 Zheng, G, Sayama, K, Okubo, T, et al. (2004) Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo 18, 5562.Google ScholarPubMed
14 Lopez-Garcia, E, van Dam, RM, Rajpathak, S, et al. (2006) Changes in caffeine intake and long-term weight change in men and women. Am J Clin Nutr 83, 674680.CrossRefGoogle ScholarPubMed
15 Greenberg, JA, Axen, KV, Schnoll, R, et al. (2005) Coffee, tea and diabetes: the role of weight loss and caffeine. Int J Obes (Lond) 29, 11211129.CrossRefGoogle ScholarPubMed
16 Wu, T, Willett, WC, Hankinson, SE, et al. (2005) Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 28, 13901396.CrossRefGoogle Scholar
17 Cheung, WT, Lee, CM & Ng, TB (1988) Potentiation of the anti-lipolytic effect of 2-chloroadenosine after chronic caffeine treatment. Pharmacology 36, 331339.CrossRefGoogle ScholarPubMed
18 Astrup, A, Breum, L, Toubro, S, et al. (1992) The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord 16, 269277.Google Scholar
19 Sung, BH, Whitsett, TL, Lovallo, WR, et al. (1994) Prolonged increase in blood pressure by a single oral dose of caffeine in mildly hypertensive men. Am J Hypertens 7, 755758.CrossRefGoogle ScholarPubMed
20 Sung, BH, Lovallo, WR, Whitsett, T, et al. (1995) Caffeine elevates blood pressure response to exercise in mild hypertensive men. Am J Hypertens 8, 11841188.CrossRefGoogle ScholarPubMed
21 Pincomb, GA, Lovallo, WR, McKey, BS, et al. (1996) Acute blood pressure elevations with caffeine in men with borderline systemic hypertension. Am J Cardiol 77, 270274.CrossRefGoogle ScholarPubMed
22 Benowitz, NL (1990) Clinical pharmacology of caffeine. Annu Rev Med 41, 277288.CrossRefGoogle ScholarPubMed
23 Fredholm, BB, Battig, K, Holmen, J, et al. (1999) Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 51, 83133.Google ScholarPubMed
24 Robertson, D, Wade, D, Workman, R, et al. (1981) Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 67, 11111117.CrossRefGoogle Scholar
25 Myers, MG (1988) Effects of caffeine on blood pressure. Arch Intern Med 148, 11891193.CrossRefGoogle ScholarPubMed
26 Holtzman, SG & Finn, IB (1988) Tolerance to behavioral effects of caffeine in rats. Pharmacol Biochem Behav 29, 411418.CrossRefGoogle ScholarPubMed
27 Gasior, M, Shoaib, M, Yasar, S, et al. (1999) Acquisition of nicotine discrimination and discriminative stimulus effects of nicotine in rats chronically exposed to caffeine. J Pharmacol Exp Ther 288, 10531073.Google ScholarPubMed
28 Shearer, J, Severson, DL, Su, L, et al. (2009) Partial A1 adenosine receptor agonist regulates cardiac substrate utilization in insulin-resistant rats in vivo. J Pharmacol Exp Ther 328, 306311.CrossRefGoogle ScholarPubMed
29 Ribeiro, RT, Lautt, WW, Legare, DJ, et al. (2005) Insulin resistance induced by sucrose feeding in rats is due to an impairment of the hepatic parasympathetic nerves. Diabetologia 48, 976983.CrossRefGoogle Scholar
30 Gasior, M, Jaszyna, M, Munzar, P, et al. (2002) Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology (Berl) 162, 385395.CrossRefGoogle ScholarPubMed
31 Rodriguez-Perez, JC, Losada, A, Anabitarte, A, et al. (1997) Effects of the novel multiple-action agent carvedilol on severe nephrosclerosis in renal ablated rats. J Pharmacol Exp Ther 283, 336344.Google ScholarPubMed
32 Monzillo, LU & Hamdy, O (2003) Evaluation of insulin sensitivity in clinical practice and in research settings. Nutr Rev 61, 397412.CrossRefGoogle ScholarPubMed
33 Kim, SP, Ellmerer, M, Van Citters, GW, et al. (2003) Primacy of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate-fat diet in the dog. Diabetes 52, 24532460.CrossRefGoogle ScholarPubMed
34 Ismail, NA, El Denshary, EE & Montague, W (1977) Adenosine and the regulation of insulin secretion by isolated rat islets of Langerhans. Biochem J 164, 409413.CrossRefGoogle ScholarPubMed
35 Kanazawa, M, Xue, CY, Kageyama, H, et al. (2003) Effects of a high-sucrose diet on body weight, plasma triglycerides, and stress tolerance. Nutr Rev 61, S27S33.CrossRefGoogle ScholarPubMed
36 Delarue, J & Magnan, C (2007) Free fatty acids and insulin resistance. Curr Opin Clin Nutr Metab Care 10, 142148.CrossRefGoogle ScholarPubMed
37 Lewis, GF, Carpentier, A, Adeli, K, et al. (2002) Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23, 201229.CrossRefGoogle ScholarPubMed
38 Egawa, T, Hamada, T, Kameda, N, et al. (2009) Caffeine acutely activates 5′adenosine monophosphate-activated protein kinase and increases insulin-independent glucose transport in rat skeletal muscles. Metabolism 58, 16091617.CrossRefGoogle ScholarPubMed
39 Raney, MA & Turcotte, LP (2008) Evidence for the involvement of CaMKII and AMPK in Ca2+-dependent signaling pathways regulating FA uptake and oxidation in contracting rodent muscle. J Appl Physiol 104, 13661373.CrossRefGoogle ScholarPubMed
40 Dhalla, AK, Chisholm, JW, Reaven, GM, et al. (2009) A1 adenosine receptor: role in diabetes and obesity. Handb Exp Pharmacol 193, 271295.CrossRefGoogle Scholar
41 Espinal, J, Challiss, RA & Newsholme, EA (1983) Effect of adenosine deaminase and an adenosine analogue on insulin sensitivity in soleus muscle of the rat. FEBS Lett 158, 103106.CrossRefGoogle Scholar
42 Han, DH, Hansen, PA, Nolte, LA, et al. (1998) Removal of adenosine decreases the responsiveness of muscle glucose transport to insulin and contractions. Diabetes 47, 16711675.CrossRefGoogle ScholarPubMed
43 Vergauwen, L, Hespel, P & Richter, EA (1994) Adenosine receptors mediate synergistic stimulation of glucose uptake and transport by insulin and by contractions in rat skeletal muscle. J Clin Invest 93, 974981.CrossRefGoogle ScholarPubMed
44 Rusing, D, Muller, CE & Verspohl, EJ (2006) The impact of adenosine and A(2B) receptors on glucose homoeostasis. J Pharm Pharmacol 58, 16391645.CrossRefGoogle Scholar
45 Figler, RA, Wang, G, Srinivasan, S, et al. (2011) Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes 60, 669679.CrossRefGoogle ScholarPubMed
46 Umemura, T, Ueda, K, Nishioka, K, et al. (2006) Effects of acute administration of caffeine on vascular function. Am J Cardiol 98, 15381541.CrossRefGoogle ScholarPubMed
47 Scharf, G, Prustomersky, S & Huber, WW (2001) Elevation of glutathione levels by coffee components and its potential mechanisms. Adv Exp Med Biol 500, 535539.CrossRefGoogle ScholarPubMed
48 Varma, SD & Hegde, KR (2010) Prevention of oxidative damage to lens by caffeine. J Ocul Pharmacol Ther 26, 7377.CrossRefGoogle ScholarPubMed
49 Mytilineou, C, Kramer, BC & Yabut, JA (2002) Glutathione depletion and oxidative stress. Parkinsonism Relat Disord 8, 385387.CrossRefGoogle ScholarPubMed
50 Jackisch, R, Fehr, R & Hertting, G (1985) Adenosine: an endogenous modulator of hippocampal noradrenaline release. Neuropharmacology 24, 499507.CrossRefGoogle ScholarPubMed
51 Tseng, CJ, Chan, JY, Lo, WC, et al. (2001) Modulation of catecholamine release by endogenous adenosine in the rat adrenal medulla. J Biomed Sci 8, 389394.CrossRefGoogle ScholarPubMed
52 Robertson, D, Frolich, JC, Carr, RK, et al. (1978) Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 298, 181186.CrossRefGoogle ScholarPubMed
53 Debrah, K, Haigh, R, Sherwin, R, et al. (1995) Effect of acute and chronic caffeine use on the cerebrovascular, cardiovascular and hormonal responses to orthostasis in healthy volunteers. Clin Sci (Lond) 89, 475480.CrossRefGoogle ScholarPubMed
54 Carella, AM, Antonucci, G, Conte, M, et al. (2010) Antihypertensive treatment with β-blockers in the metabolic syndrome: a review. Curr Diabetes Rev 6, 215221.CrossRefGoogle ScholarPubMed
55 Bhatt, P, Makwana, D, Santani, D, et al. (2007) Comparative effectiveness of carvedilol and propranolol on glycemic control and insulin resistance associated with l-thyroxin-induced hyperthyroidism – an experimental study. Can J Physiol Pharmacol 85, 514520.CrossRefGoogle ScholarPubMed
56 Kveiborg, B, Christiansen, B, Major-Petersen, A, et al. (2006) Metabolic effects of β-adrenoceptor antagonists with special emphasis on carvedilol. Am J Cardiovasc Drugs 6, 209217.CrossRefGoogle ScholarPubMed
57 Corsetti, G, Pasini, E, Assanelli, D, et al. (2007) Acute caffeine administration decreased NOS and Bcl2 expression in rat skeletal muscles. Pharmacol Res 55, 96103.CrossRefGoogle ScholarPubMed
58 Ofluoglu, E, Pasaoglu, H & Pasaoglu, A (2009) The effects of caffeine on l-arginine metabolism in the brain of rats. Neurochem Res 34, 395399.CrossRefGoogle ScholarPubMed
59 Guarino, MP & Macedo, MP (2006) Co-administration of glutathione and nitric oxide enhances insulin sensitivity in Wistar rats. Br J Pharmacol 147, 959965.CrossRefGoogle ScholarPubMed
60 Guarino, MP, Correia, NC, Raposo, J, et al. (2001) Nitric oxide synthase inhibition decreases output of hepatic insulin sensitizing substance (HISS), which is reversed by SIN-1 but not by nitroprusside. Proc West Pharmacol Soc 44, 2526.Google Scholar
61 Shi, D & Daly, JW (1999) Chronic effects of xanthines on levels of central receptors in mice. Cell Mol Neurobiol 19, 719732.CrossRefGoogle ScholarPubMed
62 Stonehouse, AH, Adachi, M, Walcott, EC, et al. (2003) Caffeine regulates neuronal expression of the dopamine 2 receptor gene. Mol Pharmacol 64, 14631473.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Effect of chronic caffeine intake (1 g/l) on glycaemia and insulinaemia in control rats and in rats fed high-fat and high-sucrose diets(Mean values with their standard errors for all the individual samples obtained from 9–15 rats)

Figure 1

Fig. 1 Effect of chronic caffeine intake (1 g/l) on insulin sensitivity in control, high-fat (HF) and high-sucrose (HSu) diet rats, determined by the insulin tolerance test, expressed as constant rate for glucose disappearance (KITT). (□), Without caffeine (n 9–12); (■), with caffeine (n 12–15). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: *P < 0·05, **P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: † P < 0·05, †† P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test).

Figure 2

Fig. 2 Effect of chronic caffeine intake (1 g/l) on mean arterial pressure (MAP) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (□), Without caffeine (n 9–12); (■), with caffeine (n 9–15). Values are means, with standard errors represented by vertical bars. ** Mean value was significantly different from that of the control rats not given caffeine (P < 0·01; two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: †P < 0·05, ††P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test).

Figure 3

Fig. 3 Effect of chronic caffeine intake (1 g/l) on body-weight increment, calculated as total weight variation during the experimental period (a), visceral fat, weighed post-mortem and corrected to body weight (b) and serum NEFA (c) in control, high-fat (HF) and high-sucrose (HSu) diet rats. (□), Without caffeine (n 10–12, n 9–12 and n 9–12 for body-weight increment, visceral fat and NEFA, respectively); (■), with caffeine (n 12–16, n 9–13 and n 10–15 for body-weight increment, visceral fat and NEFA, respectively). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: ** P < 0·01, *** P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). ††† Mean value was significantly different from that of the rats within the same diet group not given caffeine (P < 0·001; two-way ANOVA with Bonferroni multiple comparison test).

Figure 4

Fig. 4 Effect of chronic caffeine intake (1 g/l) on the correlations between insulin sensitivity, visceral fat and NEFA in all the animals tested. (a) Caffeine eliminates the correlation between constant rate for glucose disappearance (KITT) and visceral fat mass. (b) Caffeine eliminates the correlation between KITT and serum NEFA. Pearson correlation coefficient was in (a): r − 0·467, P = 0·0071 without caffeine (□, - - -) and r − 0·181, P = 0·314 with caffeine (■, ––); in (b): r − 0·444, P = 0·014 without caffeine (Δ, - - -) and r − 0·148, P = 0·338 with caffeine (▲, - - -). Data represent all the individual samples obtained from control, high-fat and high-sucrose diet rats.

Figure 5

Fig. 5 Effect of chronic caffeine intake (1 g/l) on biomarkers of oxidative status. (a) Effect of caffeine on total hepatic glutathione in control rats and in rats submitted to high-fat (HF) and high-sucrose (HSu) diets. (b) Effect of caffeine on plasma NO/NO3 in control, HF and HSu rats. (□), Without caffeine (n 8–11 and n 8–13 for glutathione and NO, respectively); (■), with caffeine (n 8–12 and n 6–12, for glutathione and NO, respectively). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P < 0·01, ***P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test).

Figure 6

Fig. 6 Effect of chronic caffeine intake (1 g/l) on plasma catecholamine concentration in control, high-sucrose (HSu) and high-fat (HF) diet rats. (a) Effect of caffeine on catecholamine (adrenaline plus noradrenaline) plasma levels. (□), Without caffeine (n 10–16); (■), with caffeine (n 12–16). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats not given caffeine: **P < 0·01, ***P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group not given caffeine: †† P < 0·01, ††† P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). (b) Caffeine treatment does not change the correlation between constant rate for glucose disappearance (KITT) and circulating catecholamine (adrenaline plus noradrenaline) plasma levels. Pearson correlation coefficient was r − 0·399, P = 0·0484 without caffeine (○) and r − 0·419, P = 0·009 with caffeine (●). Data represent all the individual samples obtained from control, HF and HSu rats.

Figure 7

Fig. 7 Effect of carvedilol (CVD, 0·2 g/l) and its vehicle, methylcellulose (MC, 0·5 %), on insulin sensitivity and plasma catecholamines in control, high-fat (HF) and high-sucrose (HSu) diet rats. (a) The effect of CVD on insulin sensitivity was determined by the insulin tolerance test and is expressed as constant rate for glucose disappearance (KITT). (□), MC (n 10–17); (■), CVD (n 7–12). Values are means, with standard errors represented by vertical bars. Mean value was significantly different from that of the control rats given MC: *P < 0·05, **P < 0·01 (two-way ANOVA with Bonferroni multiple comparison test). Mean value was significantly different from that of the rats within the same diet group given MC: †P < 0·05, †††P < 0·001 (two-way ANOVA with Bonferroni multiple comparison test). (b) Effect of CVD on catecholamine (adrenaline plus noradrenaline) plasma levels. (□), MC (n 10–36); (■), CVD (n 5–7). Values are means, with standard errors represented by vertical bars. * Mean value was significantly different from that of the control rats given MC (P < 0·05; two-way ANOVA with Bonferroni multiple comparison test).